Example: Heart Attack

Search clinical trials for: Androgen Receptor Antagonists

Total 592 results

NCT02987829

Completed

Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients

Conditions: Metastatic Castrate-resistant Prostate Cancer; Adenocarcinoma, Prostate
NCT00326586

Completed

A Phase I Dose-Escalation Study of BMS-641988 in Patients With Castration-Resistant Prostate Cancer

Conditions: Prostate Cancer
NCT00103376

Terminated

Bortezomib With or Without Hormone Therapy in Treating Patients With Relapsed Prostate Cancer

Conditions: Prostate Cancer
NCT02949284

Recruiting

Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery

Conditions: Stage II Prostate Adenocarcinoma; Stage III Prostate Adenocarcinoma
NCT03899467

Recruiting

the Safety and Tolerability of Proxalutamide (GT0918) in Subjects With Metastatic Castrate Resistant Prostate Cancer

Conditions: Metastatic Castrate Resistant Prostate Cancer (mCRPC)
NCT02826772

Completed

Safety, Tolerability, and PK of GT0918 (Proxalutamide) in Subjects With Metastatic Castrate Prostate Cancer

Conditions: Metastatic Castrate Resistant Prostate Cancer (mCRPC)
NCT04631601

Recruiting

Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)

Conditions: Metastatic Castration-resistant Prostate Cancer
NCT03004534

Completed

A Study to Evaluate Changes in Human Breast Cancer Tissue Following Short-Term Use of Darolutamide

Conditions: Breast Cancer Female
NCT02464891

Terminated

Complement Inhibition in aHUS Dialysis Patients

Conditions: Atypical Hemolytic Uremic Syndrome
NCT02458716

Completed

Cytoreductive Prostatectomy in Treating Patients With Newly Diagnosed, Metastatic Prostate Cancer

Conditions: Metastatic Prostate Carcinoma; Metastatic Prostatic Adenocarcinoma; Prostate Carcinoma Metastatic to the Bone
NCT02353988

Unknown status

AR-inhibitor Bicalutamide in Treating Patients With TNBC

Conditions: Breast Neoplasms
NCT02580448

Completed

CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448)

Conditions: Cancer of the Breast; Breast Cancer; Advanced Breast Cancer; Metastatic Breast Cancer; Male Breast Cancer; Triple Negative Breast Cancer; ER+ Breast Cancer
NCT03207529

Recruiting

Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer

Conditions: Advanced Breast Carcinoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Androgen Receptor Positive; HER2/Neu Negative; Metastatic Breast Carcinoma; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8; PTEN Positive; Recurrent Breast Carcinoma; Refractory Breast Carcinoma; Triple-Negative Breast Carcinoma
NCT03531827

Recruiting

Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment

Conditions: Metastatic Castration Resistant Prostate Cancer; Prostate Neoplasms
NCT02582749

Terminated

Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases

Conditions: Prostate Cancer; Bone Metastases; Prostate Neoplasms
NCT01875250

Completed

Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer

Conditions: Prostate Cancer
NCT01867333

Active, not recruiting

Enzalutamide With or Without Vaccine Therapy for Advanced Prostate Cancer

Conditions: Prostate Cancer
NCT02849990

Completed

A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy

Conditions: Stage III Prostate Adenocarcinoma AJCC v7; Stage III Prostate Cancer AJCC v7; Stage IV Prostate Adenocarcinoma AJCC v7; Stage IV Prostate Cancer AJCC v7
NCT03124433

Completed

Neoadjuvant Apalutamide (ARN509) and Radical Prostatectomy in Treatment of Intermediate to High Risk Prostate Cancer

Conditions: Cancer of the Prostate
NCT02972060

Recruiting

ODM-201 vs Androgen Deprivation Therapy in Hormone naïve Prostate Cancer

Conditions: Prostate Cancer
NCT04409288

Recruiting

Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or Metastatic Hormone-Sensitive Prostate Cancer

Conditions: Prostate Cancer
NCT04502901

Active, not recruiting

the Safety, Tolerability and PK of KX-826 in Healthy Males With Alopecia Following Topical Multiple Dose Ascending

Conditions: Androgenetic Alopecia
NCT01337518

Suspended

A Phase 1a/1b Study to Evaluate the Safety of EZN-4176, in Adult Patients With Castration-Resistant Prostate Cancer

Conditions: Prostatic Neoplasm
NCT03805399

Recruiting

FUSCC Refractory TNBC Umbrella (FUTURE)

Conditions: Triple-negative Breast Cancer
NCT01222650

Completed

A Comparative Study of KSO-0400 in BPH Patients With LUTS

Conditions: Benign Prostatic Hyperplasia (BPH)